Homology Medicines is a biotechnology business based in the US. Homology Medicines shares (FIXX) are listed on the NASDAQ and all prices are listed in US Dollars. Homology Medicines employs 7 staff and has a trailing 12-month revenue of around $1.2 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.00 |
|---|---|
| 52-week range | $8.24 - $26.64 |
| 50-day moving average | $13.80 |
| 200-day moving average | $16.10 |
| Wall St. target price | $1.50 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-35.10 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0 from 2024-04-05
| 1 week (2024-06-23) | nan% |
|---|---|
| 1 month (2024-05-31) | nan% |
| 3 months (2024-03-31) | nan% |
| 6 months (2024-01-04) | -100.00% |
| 1 year (2023-07-03) | -100.00% |
|---|---|
| 2 years (2022-07-01) | -100.00% |
| 3 years (2021-07-02) | 6.99 |
| 5 years (2019-07-03) | 18.82 |
| Revenue TTM | $1.2 million |
|---|---|
| Gross profit TTM | $-95,143,000 |
| Return on assets TTM | -36.4% |
| Return on equity TTM | -90.02% |
| Profit margin | 0% |
| Book value | $22.65 |
| Market Capitalization | $3 million |
TTM: trailing 12 months
We're not expecting Homology Medicines to pay a dividend over the next 12 months.
Homology Medicines's shares were split on a 1:18 basis on 24 March 2024. So if you had owned 18 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Homology Medicines shares – just the quantity. However, indirectly, the new 1700% higher share price could have impacted the market appetite for Homology Medicines shares which in turn could have impacted Homology Medicines's share price.
Over the last 12 months, Homology Medicines's shares have ranged in value from as little as $8.244 up to $26.64. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Homology Medicines's is -0.107. This would suggest that Homology Medicines's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Homology Medicines has bucked the trend.
Homology Medicines, Inc. , a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts. .
Learn the basics of call options: what they are, how they work and examples.
These are the 10 best stocks to buy right now, trading on the Nasdaq and NYSE.
Features and fees to consider before you open an account with this trading platform.
Compare pros, cons, research tools and reviews for these two trading platforms.
What you need to know about investing in the leading indicator for the overall US stock market.
There are many ways to invest and grow $50K depending on your financial situation, personal needs and goals.
Take advantage of commission-free trading with stocks, ETFs and options with a flexible trading platform.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
Check out the best-performing ETFs so far in 2024.